Trial Profile

A phase 2 study to test the efficacy and safety of BIO101 (20-hydroxyecdysone) in patients with obesity and overweight with secondary comorbidities, who are starting treatment with GLP-1 RAs for weight loss

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jul 2025 According to a Biophytis media release, company announced with first patients expected to be enrolled later this year.
04 Jun 2025 According to a Biophytis media release, this study will be presented at he BIO International Convention, which will take place this year in Boston, USA, from June 16 to 19, 2025.
08 Jan 2025 According to a Biophytis media release, company announces the completion of a refinancing transaction for a targeted total amount of 8.6 million euro, allowing it to solidify its financial structure with the arrival of new investors and to launch the Phase 2 OBA study in the United States. The study is expected to begin in first half of 2025 in the USA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com